Difference between revisions of "Houot R, et al. Ann. Oncol. (2016) cited as Ref 609 in DOI: 10.1038/s41392-020-0110-5 (Q9872)"
Jump to navigation
Jump to search
(Created claim: PubMed ID (P140): 27002105, #quickstatements; #temporary_batch_1590001671040) |
(Created claim: Page(s) (P105): 1349-1350, #quickstatements; #temporary_batch_1590074839150) |
||||||||||||||
| (4 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2016
| ||||||||||||||
| Property / Publication Date: 2016 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | Ann. Oncol. | ||||||||||||||
| Property / Published In Name String: Ann. Oncol. / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Volume | |||||||||||||||
| + | 27 | ||||||||||||||
| Property / Volume: 27 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / title | |||||||||||||||
| + | Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA (English) | ||||||||||||||
| Property / title: Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Page(s) | |||||||||||||||
| + | 1349-1350 | ||||||||||||||
| Property / Page(s): 1349-1350 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
Latest revision as of 15:46, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Houot R, et al. Ann. Oncol. (2016) cited as Ref 609 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Houot R
0 references
2016
0 references
Ann. Oncol.
0 references
27
0 references
Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA (English)
0 references
1349-1350
0 references
